Eltrombopag Olamine Tablets 25mg
TROMLIEVA 25 MG (Eltrombopag Olamine Tablets 25 mg) is a prescription medicine containing Eltrombopag Olamine 25 mg, a thrombopoietin receptor agonist used to increase platelet production in patients suffering from certain blood disorders associated with low platelet counts. It is commonly prescribed for the treatment of Chronic Immune Thrombocytopenia (ITP), Severe Aplastic Anemia, and thrombocytopenia associated with chronic hepatitis C infection.
Platelets are essential blood components that help the body form clots and prevent excessive bleeding. When platelet levels become abnormally low, patients may experience symptoms such as easy bruising, prolonged bleeding, nosebleeds, bleeding gums, fatigue, and the appearance of tiny red or purple spots on the skin. TROMLIEVA 25 MG helps stimulate the body's natural platelet production process, reducing the risk of bleeding complications.
Eltrombopag works by activating thrombopoietin receptors found in the bone marrow. These receptors play a key role in the production of platelets. By stimulating these receptors, TROMLIEVA 25 MG encourages the bone marrow to produce more platelets, helping restore healthier platelet levels in the bloodstream.
Unlike platelet transfusions that provide only temporary support, Eltrombopag promotes sustained platelet production by the body's own cells, making it an effective long-term treatment option for many eligible patients.
TROMLIEVA 25 MG is commonly prescribed for:
Chronic Immune Thrombocytopenia (ITP)
Severe Aplastic Anemia (SAA)
Hepatitis C-Associated Thrombocytopenia
Bone Marrow Failure Disorders
Platelet Production Support Therapy
Long-Term Management of Low Platelet Counts
Hematology Treatment Programs
Blood Disorder Management
The medicine may be prescribed when conventional therapies have failed to provide adequate improvement in platelet counts or when long-term platelet management is required.
Manufactured under stringent pharmaceutical quality standards, TROMLIEVA 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Eltrombopag therapy typically require regular blood tests, platelet monitoring, liver function assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven ability to stimulate platelet production, TROMLIEVA 25 MG has become an important therapeutic option in modern hematology practice.
View Details
Temozolomide Capsules IP 250mg
TEMALIEVA 250 MG (Temozolomide Capsules IP 250 mg) is a prescription anticancer medicine containing Temozolomide 250 mg, an oral chemotherapy agent used primarily for the treatment of certain types of brain tumors. It belongs to a class of medicines known as alkylating agents, which work by damaging the DNA of cancer cells, preventing them from growing and multiplying.
Brain tumors can be aggressive and difficult to treat due to their location and complex nature. Temozolomide has become an important component of modern neuro-oncology treatment because of its ability to cross the blood-brain barrier and directly target tumor cells within the brain. This unique characteristic makes it particularly effective in the management of specific malignant brain tumors.
TEMALIEVA 250 MG is commonly prescribed for patients diagnosed with Glioblastoma Multiforme (GBM), one of the most aggressive forms of brain cancer, and Anaplastic Astrocytoma, a malignant brain tumor arising from astrocyte cells. It may be used alone or in combination with radiation therapy and other treatment modalities as part of a comprehensive cancer management plan.
Unlike many traditional chemotherapy medicines that require intravenous administration, Temozolomide is available in capsule form, offering greater convenience and flexibility for patients undergoing long-term treatment.
The medicine is often prescribed during both initial treatment and maintenance therapy phases, depending on the patient’s diagnosis, treatment response, and oncologist's recommendations.
TEMALIEVA 250 MG is commonly used for:
Glioblastoma Multiforme (GBM)
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma
Anaplastic Astrocytoma
Malignant Brain Tumors
Central Nervous System (CNS) Tumors
Maintenance Chemotherapy Programs
Neuro-Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Temozolomide therapy require regular blood tests, complete blood count monitoring, liver function assessments, and clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy in brain cancer treatment, TEMALIEVA 250 MG has become a trusted option in modern oncology and neuro-oncology care worldwide.
View Details
Temozolomide Capsules IP 100 mg
TEMALIEVA 100 MG (Temozolomide Capsules IP 100 mg) is a prescription anticancer medicine containing Temozolomide 100 mg, an oral chemotherapy drug widely used in the treatment of certain malignant brain tumors. It belongs to a class of medicines known as alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from growing, multiplying, and spreading.
Brain tumors are among the most complex cancers to treat due to their location within the central nervous system. One of the major advantages of Temozolomide is its ability to cross the blood-brain barrier, allowing it to directly target cancer cells within the brain. This characteristic has made Temozolomide a cornerstone treatment in modern neuro-oncology.
TEMALIEVA 100 MG is commonly prescribed for patients diagnosed with Glioblastoma Multiforme (GBM), the most aggressive type of primary brain cancer, and Anaplastic Astrocytoma, a high-grade malignant brain tumor. It may be used as part of initial treatment, maintenance therapy, or recurrent tumor management depending on the patient's condition and oncologist's recommendations.
Unlike many traditional chemotherapy medicines that require intravenous administration, TEMALIEVA 100 MG is available in capsule form, making treatment more convenient for eligible patients while supporting long-term cancer management.
Temozolomide has become an important component of comprehensive brain cancer treatment programs because it can be used alone or alongside radiation therapy to improve disease control and treatment outcomes.
TEMALIEVA 100 MG is commonly prescribed for:
Glioblastoma Multiforme (GBM)
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma
Anaplastic Astrocytoma
Malignant Brain Tumors
Central Nervous System (CNS) Tumors
Maintenance Chemotherapy Programs
Neuro-Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Temozolomide therapy require regular medical supervision, including complete blood count monitoring, liver function assessments, infection screening, and clinical evaluations to ensure safe and effective treatment.
Due to its proven effectiveness in brain tumor management, TEMALIEVA 100 MG has become a trusted treatment option in oncology centers worldwide.
View Details
Temozolomide Capsules IP 20mg
TEMALIEVA 20 MG (Temozolomide Capsules IP 20 mg) is a prescription anticancer medicine containing Temozolomide 20 mg, an oral chemotherapy agent used in the treatment of specific malignant brain tumors. Temozolomide belongs to the class of medicines known as alkylating agents, which work by damaging the DNA of cancer cells and preventing them from growing, multiplying, and spreading.
Temozolomide is widely recognized in neuro-oncology because of its unique ability to cross the blood-brain barrier, enabling it to reach and act directly on tumor cells within the brain. This characteristic makes it an important treatment option for patients with aggressive and difficult-to-treat brain cancers.
TEMALIEVA 20 MG is commonly prescribed for the treatment of Glioblastoma Multiforme (GBM), the most aggressive form of primary brain cancer, and Anaplastic Astrocytoma, a high-grade malignant brain tumor. It may be used during initial treatment, maintenance therapy, or management of recurrent disease based on the patient’s condition and oncologist’s recommendations.
The 20 mg strength is often used as part of individualized dosing regimens, allowing oncologists to accurately adjust doses according to body surface area (BSA), treatment cycles, and patient-specific requirements.
Unlike intravenous chemotherapy, TEMALIEVA 20 MG is administered orally, providing convenience and flexibility while supporting long-term cancer treatment plans.
TEMALIEVA 20 MG is commonly used for:
Glioblastoma Multiforme (GBM)
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma
Anaplastic Astrocytoma
Malignant Brain Tumors
Central Nervous System (CNS) Tumors
Maintenance Chemotherapy Programs
Neuro-Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 20 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients undergoing Temozolomide treatment require regular blood count monitoring, liver function testing, and clinical evaluations to ensure safe and effective therapy.
Due to its established role in brain tumor treatment, TEMALIEVA 20 MG remains a valuable option in modern oncology and neuro-oncology care.
View Details
Lenalidomide Capsules 25mg
LENALIEVA 25 MG (Lenalidomide Capsules 25 mg) is a prescription anticancer and immunomodulatory medicine containing Lenalidomide 25 mg, a highly effective treatment used for certain blood cancers and hematological disorders. It belongs to a class of medicines known as Immunomodulatory Agents (IMiDs) that help the body's immune system fight cancer cells while also inhibiting tumor growth and blood vessel formation.
Lenalidomide has become a cornerstone therapy in modern hematology and oncology due to its ability to target cancer cells through multiple mechanisms. It enhances immune cell activity, suppresses abnormal cell growth, and interferes with the development of blood vessels that tumors need to survive and spread.
LENALIEVA 25 MG is widely prescribed for patients with Multiple Myeloma, Myelodysplastic Syndromes (MDS) associated with deletion 5q abnormalities, Mantle Cell Lymphoma (MCL), and certain other blood-related cancers. It may be used alone or in combination with other anticancer therapies depending on the patient's condition and treatment plan.
The medicine is often recommended for long-term treatment and maintenance therapy to help control disease progression, improve treatment outcomes, and support prolonged remission in eligible patients.
LENALIEVA 25 MG is commonly prescribed for:
Multiple Myeloma
Newly Diagnosed Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Myelodysplastic Syndromes (MDS)
MDS with Deletion 5q Abnormality
Mantle Cell Lymphoma (MCL)
Hematological Malignancies
Maintenance Therapy Programs
Advanced Hematology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, LENALIEVA 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenalidomide therapy require regular blood tests, complete blood count monitoring, kidney function assessments, and clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy in blood cancer management, LENALIEVA 25 MG has become an essential medicine in modern oncology and hematology practice worldwide.
View Details
Lenalidomide Capsules 10mg
LENALIEVA 10 MG (Lenalidomide Capsules 10 mg) is a prescription anticancer and immunomodulatory medicine containing Lenalidomide 10 mg, a widely used treatment for specific blood cancers and bone marrow disorders. It belongs to the class of medicines known as Immunomodulatory Agents (IMiDs), which work by enhancing the body's immune response against cancer cells, inhibiting abnormal cell growth, and reducing the formation of blood vessels that support tumor development.
Lenalidomide has become a key component of modern hematology and oncology treatment protocols due to its ability to target cancer through multiple mechanisms. It helps strengthen immune system activity, suppresses cancer cell proliferation, and interferes with the microenvironment that allows cancer cells to survive and spread.
LENALIEVA 10 MG is commonly prescribed for the treatment of Multiple Myeloma, Myelodysplastic Syndromes (MDS) associated with deletion 5q abnormalities, Mantle Cell Lymphoma (MCL), and certain other hematological malignancies. It may be used as part of combination therapy or maintenance treatment depending on the patient's condition and clinical requirements.
The 10 mg strength is frequently used for individualized treatment plans, dose adjustments, maintenance therapy, and patients requiring lower doses based on treatment response or kidney function.
LENALIEVA 10 MG is commonly prescribed for:
Multiple Myeloma
Newly Diagnosed Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Maintenance Therapy After Multiple Myeloma Treatment
Myelodysplastic Syndromes (MDS)
MDS with Deletion 5q Abnormality
Mantle Cell Lymphoma (MCL)
Hematological Malignancies
Long-Term Blood Cancer Management
Manufactured according to stringent pharmaceutical quality standards, LENALIEVA 10 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenalidomide therapy require regular blood count monitoring, kidney function testing, liver assessments, and routine clinical evaluations to ensure optimal treatment outcomes and safety.
Due to its proven efficacy and versatile clinical applications, LENALIEVA 10 MG remains an important medicine in modern hematology and oncology care.
View Details
Lenalidomide Capsules 5mg
LENALIEVA 5 MG (Lenalidomide Capsules 5 mg) is a prescription anticancer and immunomodulatory medicine containing Lenalidomide 5 mg, used in the treatment of certain blood cancers and bone marrow disorders. Lenalidomide belongs to a class of medicines known as Immunomodulatory Drugs (IMiDs), which help the immune system identify and attack abnormal cells while also inhibiting cancer cell growth and reducing the formation of blood vessels that support tumor development.
Lenalidomide plays an important role in modern hematology and oncology by targeting cancer through multiple pathways. It enhances immune function, suppresses the growth of abnormal cells, promotes cancer cell death, and interferes with the tumor microenvironment that enables disease progression.
LENALIEVA 5 MG is widely prescribed for patients with Multiple Myeloma, Myelodysplastic Syndromes (MDS) associated with deletion 5q abnormalities, and Mantle Cell Lymphoma (MCL). It may be used alone or in combination with other therapies depending on the patient's diagnosis, treatment stage, and clinical requirements.
The 5 mg strength is commonly used for maintenance therapy, dose adjustments, elderly patients, and individuals requiring lower doses due to kidney impairment or treatment-related side effects. It allows oncologists to tailor therapy according to each patient's specific needs.
LENALIEVA 5 MG is commonly prescribed for:
Multiple Myeloma
Maintenance Therapy After Multiple Myeloma Treatment
Relapsed or Refractory Multiple Myeloma
Myelodysplastic Syndromes (MDS)
MDS with Deletion 5q Abnormality
Mantle Cell Lymphoma (MCL)
Hematological Malignancies
Long-Term Blood Cancer Management
Individualized Lenalidomide Therapy Programs
Manufactured according to stringent pharmaceutical quality standards, LENALIEVA 5 MG is designed to deliver consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenalidomide therapy require regular blood count monitoring, kidney function tests, liver assessments, and routine medical evaluations to ensure optimal treatment outcomes and safety.
Due to its established clinical benefits, LENALIEVA 5 MG remains an important component of modern blood cancer treatment strategies.
View Details
Sunitinib Malate Capsules 50mg
SUNITCAP 50 MG (Sunitinib Malate Capsules 50 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 50 mg, a potent Tyrosine Kinase Inhibitor (TKI) used in the treatment of various advanced cancers. It works by blocking specific proteins that promote cancer cell growth and the formation of blood vessels that supply nutrients to tumors.
Cancer cells require a continuous blood supply to grow and spread. Sunitinib helps inhibit angiogenesis (the formation of new blood vessels) and interferes with signaling pathways that cancer cells use for survival and proliferation. This targeted mechanism makes it an effective treatment option for several solid tumors.
Unlike traditional chemotherapy, which affects both healthy and cancerous rapidly dividing cells, Sunitinib specifically targets molecular pathways involved in tumor growth, helping to improve treatment outcomes while supporting long-term disease management.
SUNITCAP 50 MG is commonly prescribed for:
Advanced Renal Cell Carcinoma (Kidney Cancer)
Gastrointestinal Stromal Tumors (GIST)
Pancreatic Neuroendocrine Tumors (pNET)
Metastatic Kidney Cancer
Advanced Solid Tumors
Targeted Cancer Therapy Programs
Long-Term Oncology Management
Precision Oncology Treatment Protocols
The medicine may be used as a first-line treatment or after failure of other therapies, depending on the type and stage of cancer.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 50 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require routine monitoring, including blood pressure checks, blood tests, liver function assessments, thyroid evaluations, and regular clinical examinations.
Due to its proven efficacy in multiple cancer types, SUNITCAP 50 MG has become an important treatment option in modern oncology practice.
View Details
Sunitinib Malate Capsules 25mg
SUNITCAP 25 MG (Sunitinib Malate Capsules 25 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 25 mg, a potent Tyrosine Kinase Inhibitor (TKI) used for the treatment of various advanced cancers. It works by blocking specific proteins that play a critical role in cancer cell growth, tumor progression, and the development of blood vessels that supply nutrients to tumors.
Sunitinib is widely recognized in modern oncology for its targeted mechanism of action. By inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, it helps slow the progression of cancer and supports long-term disease control.
Unlike traditional chemotherapy, which may affect both healthy and cancerous cells, Sunitinib specifically targets molecular pathways associated with cancer development. This targeted approach has made it an important treatment option for several advanced and metastatic cancers.
SUNITCAP 25 MG is commonly prescribed for:
Advanced Renal Cell Carcinoma (Kidney Cancer)
Metastatic Renal Cell Carcinoma
Gastrointestinal Stromal Tumors (GIST)
Pancreatic Neuroendocrine Tumors (pNET)
Advanced Solid Tumors
Targeted Cancer Therapy Programs
Precision Oncology Treatment Plans
Long-Term Cancer Management
The 25 mg strength is often used for individualized treatment regimens, dose modifications, maintenance therapy, or patients requiring adjusted doses based on treatment response and tolerability.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require routine monitoring, including blood pressure checks, blood tests, liver function assessments, thyroid monitoring, and regular medical evaluations.
Due to its proven effectiveness in managing several advanced cancers, SUNITCAP 25 MG remains an important medicine in contemporary oncology practice.
View Details
Sunitinib Malate Capsules 12.5mg
SUNITCAP 12.5 MG (Sunitinib Malate Capsules 12.5 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 12.5 mg, a potent Tyrosine Kinase Inhibitor (TKI) used in the treatment of various advanced and metastatic cancers. Sunitinib works by blocking specific proteins responsible for cancer cell growth, tumor progression, and the formation of blood vessels that supply nutrients to tumors.
Cancer cells rely on multiple signaling pathways to grow and spread throughout the body. Sunitinib targets these pathways by inhibiting several receptor tyrosine kinases, helping to slow tumor growth and reduce the development of new blood vessels required for cancer progression. This targeted approach makes it an important option in modern oncology treatment.
Unlike conventional chemotherapy, which may affect both healthy and cancerous rapidly dividing cells, Sunitinib specifically targets molecular pathways involved in tumor development. This precision-based mechanism supports effective long-term disease management in eligible patients.
SUNITCAP 12.5 MG is commonly prescribed for:
Advanced Renal Cell Carcinoma (Kidney Cancer)
Metastatic Renal Cell Carcinoma
Gastrointestinal Stromal Tumors (GIST)
Pancreatic Neuroendocrine Tumors (pNET)
Advanced Solid Tumors
Targeted Cancer Therapy Programs
Precision Oncology Treatment Plans
Long-Term Cancer Management
The 12.5 mg strength is frequently used for dose adjustments, maintenance therapy, combination dosing schedules, and patients requiring lower doses based on individual treatment response and tolerability.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 12.5 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require regular monitoring, including blood pressure assessments, complete blood counts, liver function testing, thyroid evaluations, and clinical examinations to ensure optimal treatment outcomes.
Due to its proven effectiveness in targeted cancer therapy, SUNITCAP 12.5 MG remains an important medicine in contemporary oncology care.
View Details
Pemetrexed Injection IP 500 mg
ALIMLIEVA 500 MG (Pemetrexed Injection IP 500 mg) is a prescription anticancer medicine containing Pemetrexed 500 mg, a chemotherapy agent widely used in the treatment of certain lung cancers and malignant pleural mesothelioma. It belongs to a class of medicines known as Antifolate Antineoplastic Agents, which work by interfering with the production of DNA and RNA required for cancer cell growth and multiplication.
Cancer cells grow and divide rapidly, requiring large amounts of folate-dependent enzymes for survival. Pemetrexed blocks several key enzymes involved in the synthesis of nucleic acids, thereby slowing cancer cell growth and promoting cancer cell death. This targeted action helps control tumor progression and improve treatment outcomes.
ALIMLIEVA 500 MG is commonly prescribed for patients with Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma, either as a single agent or in combination with other anticancer medicines such as platinum-based chemotherapy. It may also be used as maintenance therapy in eligible patients to help delay disease progression.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
ALIMLIEVA 500 MG is commonly used for:
Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Squamous NSCLC
Maintenance Therapy in NSCLC
Malignant Pleural Mesothelioma
Advanced Lung Cancer Treatment
Combination Chemotherapy Programs
Oncology Treatment Protocols
Long-Term Cancer Management
Manufactured according to stringent pharmaceutical quality standards, ALIMLIEVA 500 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pemetrexed therapy generally require supplementation with folic acid and vitamin B12, along with regular blood tests and clinical monitoring to minimize side effects and optimize treatment outcomes.
Due to its established efficacy in thoracic oncology, ALIMLIEVA 500 MG remains an important medicine in modern cancer care.
View Details
Pemetrexed Injection IP 100mg
ALIMLIEVA 100 MG (Pemetrexed Injection IP 100 mg) is a prescription anticancer medicine containing Pemetrexed 100 mg, an antifolate chemotherapy agent used in the treatment of specific cancers, particularly Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma. It belongs to a class of medicines known as Antifolate Antineoplastic Agents, which work by interfering with the production of DNA and RNA required for cancer cell growth and survival.
Cancer cells require folate-dependent enzymes to replicate and spread. Pemetrexed blocks multiple enzymes involved in the synthesis of nucleic acids, thereby preventing cancer cells from multiplying and promoting their destruction. This mechanism helps slow disease progression and improve treatment outcomes.
ALIMLIEVA 100 MG is commonly used as part of combination chemotherapy regimens, maintenance therapy programs, and individualized dosing schedules. The 100 mg strength allows oncologists to accurately adjust treatment doses according to a patient’s body surface area (BSA), treatment protocol, and clinical requirements.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in cancer treatment.
ALIMLIEVA 100 MG is commonly prescribed for:
Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Squamous NSCLC
Maintenance Therapy in NSCLC
Malignant Pleural Mesothelioma
Advanced Lung Cancer Treatment
Combination Chemotherapy Programs
Oncology Treatment Protocols
Individualized Cancer Dosing Regimens
Manufactured according to stringent pharmaceutical quality standards, ALIMLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pemetrexed therapy generally require supplementation with folic acid and vitamin B12, along with routine blood tests and medical monitoring to reduce treatment-related side effects and optimize outcomes.
Due to its established efficacy in thoracic oncology, ALIMLIEVA 100 MG remains an important medicine in modern cancer care.
View Details
